

Molecular profiling of low grade serous ovarian tumour driver genes

Oncotarget

6, 37663-37677

DOI: [10.18632/oncotarget.5438](https://doi.org/10.18632/oncotarget.5438)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The genetics of uveal melanoma: current insights. <i>The Application of Clinical Genetics</i> , 2016, Volume 9, 147-155.	1.4	99
2	Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2113.	1.8	165
3	Genome-wide association studies and epigenome-wide association studies go together in cancer control. <i>Future Oncology</i> , 2016, 12, 1645-1664.	1.1	28
4	Basic Molecular Pathology and Cytogenetics for Practicing Pathologists: Correlation With Morphology and With a Focus on Aspects of Diagnostic or Therapeutic Utility. <i>Advances in Anatomic Pathology</i> , 2016, 23, 368-380.	2.4	11
5	SF3B1 and EIF1AX mutations occur in primary leptomeningeal melanocytic neoplasms; yet another similarity to uveal melanomas. <i>Acta Neuropathologica Communications</i> , 2016, 4, 5.	2.4	35
6	Perspectives on targeting the phosphatidylinositol 3-kinase pathway for personalized medicine in endometrial and ovarian cancers. <i>Personalized Medicine Universe</i> , 2016, 5, 3-7.	0.1	0
7	The molecular pathology of ovarian serous borderline tumors. <i>Annals of Oncology</i> , 2016, 27, i16-i19.	0.6	39
8	Low-grade serous ovarian cancer: A review. <i>Gynecologic Oncology</i> , 2016, 143, 433-438.	0.6	135
9	Novel population of small tumour-initiating stem cells in the ovaries of women with borderline ovarian cancer. <i>Scientific Reports</i> , 2016, 6, 34730.	1.6	44
10	p53 downregulates the Fanconi anaemia DNA repair pathway. <i>Nature Communications</i> , 2016, 7, 11091.	5.8	42
11	Molecular Subtyping of Serous Ovarian Cancer Based on Multi-omics Data. <i>Scientific Reports</i> , 2016, 6, 26001.	1.6	42
12	Genomic testing and precision medicine – What does this mean for gynecologic oncology?. <i>Gynecologic Oncology</i> , 2016, 140, 3-5.	0.6	5
13	The biology of uveal melanoma. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 109-140.	2.7	160
14	Recurrent low grade serous ovarian cancer in a 20 year old woman: A case from the Ohio State University College of Medicine. <i>Gynecologic Oncology</i> , 2017, 144, 451-455.	0.6	2
15	Precision Medicine in Gynecology and Obstetrics. <i>Comprehensive Gynecology and Obstetrics</i> , 2017, , .	0.0	1
16	A harmine-derived beta-carboline displays anti-cancer effects in vitro by targeting protein synthesis. <i>European Journal of Pharmacology</i> , 2017, 805, 25-35.	1.7	46
17	Aberrant expression of deubiquitylating enzyme USP9X predicts poor prognosis in gastric cancer. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, 687-692.	0.7	16
18	Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours. <i>Annals of Oncology</i> , 2017, 28, 718-726.	0.6	33

#	ARTICLE	IF	CITATIONS
19	Endocrine therapy in epithelial ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 109-117.	1.1	41
20	Comprehensive analyses of somatic TP53 mutation in tumors with variable mutant allele frequency. <i>Scientific Data</i> , 2017, 4, 170120.	2.4	9
21	Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma. <i>Human Pathology</i> , 2017, 68, 87-91.	1.1	19
22	<i>EIF1AX</i> and <i>NRAS</i> Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas. <i>Cancer Research</i> , 2017, 77, 4268-4278.	0.4	56
23	Molecular alterations in indolent, aggressive and recurrent ovarian low-grade serous carcinoma. <i>Histopathology</i> , 2017, 70, 347-358.	1.6	24
24	Identifying Gene Signature for the Detection of Ovarian Cancer Based on the Achieved Related Genes. <i>Gynecologic and Obstetric Investigation</i> , 2017, 82, 361-370.	0.7	4
25	CAISMOV24, a new human low-grade serous ovarian carcinoma cell line. <i>BMC Cancer</i> , 2017, 17, 756.	1.1	7
26	Low frequency of BRAF and KRAS mutations in Chinese patients with low-grade serous carcinoma of the ovary. <i>Diagnostic Pathology</i> , 2017, 12, 87.	0.9	11
27	The NCI-MATCH trial and precision medicine in gynecologic cancers. <i>Gynecologic Oncology</i> , 2018, 148, 585-590.	0.6	38
28	Emerging growth factor receptor antagonists for ovarian cancer treatment. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 1-16.	1.0	2
29	An Ovarian Adenocarcinoma With Combined Low-grade Serous and Mesonephric Morphologies Suggests a Müllerian Origin for Some Mesonephric Carcinomas. <i>International Journal of Gynecological Pathology</i> , 2018, 37, 448-459.	0.9	54
30	Targeted Next-Generation Sequencing Reveals Clinically Actionable <i>BRAF</i> and <i>ESR1</i> Mutations in Low-Grade Serous Ovarian Carcinoma. <i>JCO Precision Oncology</i> , 2018, 2018, 1-8.	1.5	8
31	Ovarian Cancer Genetics: Subtypes and Risk Factors. , 0, , .		17
32	Comparison of Primary Tumor Size in Stage I and III Epithelial Ovarian Cancer. <i>Anticancer Research</i> , 2018, 38, 6507-6511.	0.5	5
33	Pathogenesis, Genetics, and Genomics of Non-High Grade Serous Ovarian Cancers. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 929-942.	0.9	4
34	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 250-261.	1.3	70
35	Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells. <i>Medicines (Basel, Switzerland)</i> , 2018, 5, 16.	0.7	123
36	PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. <i>Gynecologic Oncology</i> , 2019, 154, 531-538.	0.6	49

#	ARTICLE	IF	CITATIONS
37	Current Status of Patient-Derived Ovarian Cancer Models. <i>Cells</i> , 2019, 8, 505.	1.8	69
38	Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer. <i>Neoplasia</i> , 2019, 21, 582-590.	2.3	24
39	Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation: A case report. <i>Gynecologic Oncology Reports</i> , 2019, 28, 26-28.	0.3	16
40	Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a004341.	0.5	8
41	Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1462-1472.	2.1	33
42	Somatic genetic alterations in synchronous and metachronous low-grade serous tumours and high-grade carcinomas of the adnexa. <i>Histopathology</i> , 2019, 74, 638-650.	1.6	11
43	New Treatment Options for Ovarian Cancer. , 2019, , 533-540.		0
44	Cancer-Associated Eukaryotic Translation Initiation Factor 1A Mutants Impair Rps3 and Rps10 Binding and Enhance Scanning of Cell Cycle Genes. <i>Molecular and Cellular Biology</i> , 2019, 39, .	1.1	13
45	MALDI-imaging for Classification of Epithelial Ovarian Cancer Histotypes from a Tissue Microarray Using Machine Learning Methods. <i>Proteomics - Clinical Applications</i> , 2019, 13, e1700181.	0.8	45
46	Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target. <i>Cancer Cell International</i> , 2019, 19, 10.	1.8	31
47	Detection of MAPK/ERK pathway proteins and KRAS mutations in adenomatoid odontogenic tumors. <i>Oral Diseases</i> , 2019, 25, 481-487.	1.5	16
48	High Frequency of PIK3CA Mutations in Low-Grade Serous Ovarian Carcinomas of Japanese Patients. <i>Diagnostics</i> , 2020, 10, 13.	1.3	9
49	Low-grade serous ovarian carcinoma: an evolution toward targeted therapy. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1619-1626.	1.2	9
50	Clinical significance of ERBB2 exon 16 skipping: analysis of a real-world retrospective observational cohort study. <i>ESMO Open</i> , 2020, 5, e000985.	2.0	4
51	Management of low-grade serous ovarian neoplasm in the setting of fertility preservation. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1834-1839.	1.2	1
52	mRNA expression in low grade serous ovarian cancer: Results of a nanoString assay in a diverse population. <i>Gynecologic Oncology</i> , 2020, 159, 554-562.	0.6	5
53	Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications. <i>European Journal of Cancer, Supplement</i> , 2020, 15, 1-15.	2.2	15
54	Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression. <i>Annals of Diagnostic Pathology</i> , 2020, 48, 151582.	0.6	1

#	ARTICLE	IF	CITATIONS
55	MEK Inhibitors for the Treatment of Low-Grade Serous Ovarian Cancer: Expanding Therapeutic Options for a Rare Ovarian Cancer Subtype. <i>Journal of Clinical Oncology</i> , 2020, 38, 3731-3734.	0.8	10
56	MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. <i>Journal of Clinical Oncology</i> , 2020, 38, 3753-3762.	0.8	82
57	Therapeutic Approach to Low-Grade Serous Ovarian Carcinoma: State of Art and Perspectives of Clinical Research. <i>Cancers</i> , 2020, 12, 1336.	1.7	27
58	Low-grade serous ovarian cancer: State of the science. <i>Gynecologic Oncology</i> , 2020, 156, 715-725.	0.6	74
59	Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma. <i>Modern Pathology</i> , 2021, 34, 490-501.	2.9	18
60	A systematic review and meta-analysis of hormone receptor expression in low-grade serous ovarian carcinoma. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 256, 172-178.	0.5	5
61	Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. <i>Journal of Pathology</i> , 2021, 253, 41-54.	2.1	54
62	Current and Futuristic Roadmap of Ovarian Cancer Management: An Overview. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1330, 1-19.	0.8	1
63	Epithelial ovarian cancer: Genomic landscape and evolving precision treatment. , 2021, , 1-23.		0
64	Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?. <i>Seminars in Cancer Biology</i> , 2021, 77, 67-82.	4.3	12
65	Ovarian Cancer: Molecular Classification and Targeted Therapy. , 0, , .		4
66	Fertility preservation in rare ovarian tumors. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 432-441.	1.2	4
67	Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms. <i>Journal of Human Genetics</i> , 2021, 66, 853-868.	1.1	5
68	Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary—Clinical significance of BRCA2 gene variants in genomically stable tumors. <i>Gynecologic Oncology</i> , 2021, 161, 762-768.	0.6	5
69	The Molecular Landscape Influencing Prognoses of Epithelial Ovarian Cancer. <i>Biomolecules</i> , 2021, 11, 998.	1.8	4
70	Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications (Review). <i>Oncology Reports</i> , 2021, 46, .	1.2	21
71	Ovarian-Cancer-Associated Extracellular Vesicles: Microenvironmental Regulation and Potential Clinical Applications. <i>Cells</i> , 2021, 10, 2272.	1.8	17
72	Molecular Pathology of Ovarian Epithelial Neoplasms. <i>Surgical Pathology Clinics</i> , 2021, 14, 415-428.	0.7	2

#	ARTICLE	IF	CITATIONS
73	RNA-binding proteins of COSMIC importance in cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	15
74	Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors. <i>Cancer Treatment Reviews</i> , 2021, 101, 102298.	3.4	11
75	Spectrum of <i>BRAF</i> Mutations and Gene Rearrangements in Ovarian Serous Carcinoma. <i>JCO Precision Oncology</i> , 2021, 5, 1480-1492.	1.5	8
76	Observational study on serum markers and circulating tumor cells in ovarian cancer. <i>IP Archives of Cytology and Histopathology Research</i> , 2021, 6, 181-186.	0.0	0
77	Multimiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability. <i>Cancer Research</i> , 2021, 81, 1681-1694.	0.4	19
78	Immunohistochemical Biomarkers as a Surrogate of Molecular Analysis in Ovarian Carcinomas: A Review of the Literature. <i>Diagnostics</i> , 2021, 11, 199.	1.3	24
79	Low-grade Serous Tumors: Are We Making Progress?. <i>Current Oncology Reports</i> , 2020, 22, 8.	1.8	13
80	Identification and validation of salivary proteomic signatures for non-invasive detection of ovarian cancer. <i>International Journal of Biological Macromolecules</i> , 2018, 108, 503-514.	3.6	23
81	The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting. <i>International Journal of Gynecological Pathology</i> , 2021, 40, 32-40.	0.9	37
82	Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. <i>Oncotarget</i> , 2017, 8, 33796-33806.	0.8	5
83	miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma. <i>Oncotarget</i> , 2016, 7, 12731-12747.	0.8	77
84	Mutation analysis and genomic imbalances of cells found in effusion fluids from patients with ovarian cancer. <i>Oncology Letters</i> , 2020, 20, 2273-2279.	0.8	3
85	An Introduction to the Current Management of Ovarian Cancer in the Era of Precision Oncology. , 2021, , 19-57.		0
86	The Role of Omics Approaches to Characterize Molecular Mechanisms of Rare Ovarian Cancers: Recent Advances and Future Perspectives. <i>Biomedicines</i> , 2021, 9, 1481.	1.4	8
87	Diversity in Pathology and Genomics in Ovarian Cancer. <i>Comprehensive Gynecology and Obstetrics</i> , 2017, , 117-126.	0.0	0
89	MEK inhibition for low-grade serous ovarian cancer: are we there yet?. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 155-156.	1.2	1
90	Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines. <i>American Journal of Cancer Research</i> , 2016, 6, 2235-2251.	1.4	14
92	Investigating a clinically actionable BRAF mutation for monitoring low-grade serous ovarian cancer: A case report. <i>Case Reports in Women's Health</i> , 2022, 34, e00395.	0.2	0

#	ARTICLE	IF	CITATIONS
93	The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. <i>Gynecologic Oncology</i> , 2022, 165, 560-567.	0.6	22
94	Ovarian Combined Serous Borderline Tumor/Low-grade Serous Carcinoma and Mesonephric-like Lesion: Report of 2 Cases With New Observations. <i>International Journal of Gynecological Pathology</i> , 2023, 42, 182-191.	0.9	8
95	Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3343.	1.8	1
96	Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells. <i>Cancers</i> , 2022, 14, 1506.	1.7	3
97	Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: Pre-clinical updates. <i>Oncotarget</i> , 2022, 13, 553-575.	0.8	6
98	The Uncertain Benefit of Adjuvant Chemotherapy in Advanced Low-Grade Serous Ovarian Cancer and the Pivotal Role of Surgical Cytoreduction. <i>Journal of Clinical Medicine</i> , 2021, 10, 5927.	1.0	9
99	MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 4456-4465.	3.2	25
101	BAP1 and Claudin-4, But Not MTAP, Reliably Distinguish Borderline and Low-grade Serous Ovarian Tumors From Peritoneal Mesothelioma. <i>International Journal of Gynecological Pathology</i> , 2023, 42, 159-166.	0.9	5
102	Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	9
103	Insights Into the Role of Epigenetic Factors Determining the Estrogen Response in Estrogen-Positive Ovarian Cancer and Prospects of Combining Epi-Drugs With Endocrine Therapy. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
104	Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22). <i>British Journal of Cancer</i> , 2022, 127, 1479-1486.	2.9	7
105	Recent Advances in Classification and Histopathological Diagnosis of Ovarian Epithelial Malignant Tumours. , 0, , .		0
106	Taking the Road Less Traveled: Following Molecular Trail Markers. <i>Clinical Cancer Research</i> , 2022, 28, 4357-4359.	3.2	2
108	Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy. <i>Gynecologic Oncology</i> , 2022, 167, 306-313.	0.6	8
109	Translational Regulation by eIFs and RNA Modifications in Cancer. <i>Genes</i> , 2022, 13, 2050.	1.0	4
110	Low-Grade Serous Ovarian Carcinoma: Challenges and Solutions. <i>Indian Journal of Gynecologic Oncology</i> , 2022, 20, .	0.1	0
111	Aberrant MAPK Signaling Offers Therapeutic Potential for Treatment of Ovarian Carcinoma. <i>OncoTargets and Therapy</i> , 0, Volume 15, 1331-1346.	1.0	3
112	Role of RAS signaling in ovarian cancer. <i>F1000Research</i> , 0, 11, 1253.	0.8	8

#	ARTICLE	IF	CITATIONS
113	Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	2
114	Investigation of the prevalence and clinical implications of ERBB2 exon 16 skipping mutations in Chinese pan-cancer patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
115	Molecular characteristics of low-grade serous carcinoma in effusions. <i>Cytopathology</i> , 2023, 34, 99-105.	0.4	0
116	Molecular characteristics and clinical behaviour of epithelial ovarian cancers. <i>Cancer Letters</i> , 2023, 555, 216057.	3.2	16
117	Serous Tumors of the Ovary. <i>Encyclopedia of Pathology</i> , 2023, , 1-12.	0.0	0
118	Genetics and RNA Regulation of Uveal Melanoma. <i>Cancers</i> , 2023, 15, 775.	1.7	8
119	Molecular genetic testing in ovarian cancer. <i>Pacific Medical Journal</i> , 2023, , 11-18.	0.0	0
120	The adaptor protein VEPH1 interacts with the kinase domain of ERBB2 and impacts EGF signaling in ovarian cancer cells. <i>Cellular Signalling</i> , 2023, 106, 110634.	1.7	0
121	Investigating the suitability of in vitro cell lines as models for the major subtypes of epithelial ovarian cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	5
122	Interobserver Reproducibility in Assessing Eosinophilic Cells in Ovarian Serous Borderline Tumors to Predict BRAF Mutational Status. <i>International Journal of Gynecological Pathology</i> , 2023, 42, 472-481.	0.9	1
123	Patient Derived Organoids (PDOs), Extracellular Matrix (ECM), Tumor Microenvironment (TME) and Drug Screening: State of the Art and Clinical Implications of Ovarian Cancer Organoids in the Era of Precision Medicine. <i>Cancers</i> , 2023, 15, 2059.	1.7	5
124	Engineering Approaches in Ovarian Cancer Cell Culture. <i>Current Cancer Research</i> , 2023, , 231-253.	0.2	0
136	Molecular Pathology of Ovarian Tumors. , 2023, , 271-296.		0
137	Serous Tumors, Pathology of the Ovary. <i>Encyclopedia of Pathology</i> , 2023, , 554-564.	0.0	0
139	The Molecular Classification of Ovarian Cancer and Implication for Treatment. , 2023, , 285-315.		0
140	Serous Tumours of the Ovary. , 2023, , 397-416.		0